

**How can the *Foundation pharmacist programme 2020/21* support my GPhC registration assessment preparation?**

Preparing for the GPhC registration assessment will understandably be a priority at this time, and you will be trying to balance this with the online learning for the modules of the *Foundation pharmacist programme 2020/21*.

Chapter 6 of the *Exam game plan*<sup>1</sup> helps accelerate your learning and introduces the iceberg model (levels of learning and revision strategies). Remember that revising from textbooks, reading the *BNF*, *NICE* guidance, local protocols and product information is just surface learning (or the ‘tip of the iceberg’). The best preparation for an exam is to engage in deep learning (or the part of the iceberg that’s below the surface). Deep learning involves applying learning in practice eg, in the workplace, and critical thinking such as problem solving.

The *Foundation pharmacist programme 2020/21* will help you develop a deep learning approach to support both your revision for the registration assessment, and your role development in the workplace, ensuring that you become a safe and effective practitioner.

In particular, the case studies and practice-based activities in Module 2 – *Applying clinical knowledge and skills with evidence informed decision making* – will help you to build on your clinical knowledge and apply this to situations that you may encounter in practice. Module 2 is also packed full of resources, such as the learning hub, which contains a wide range of really useful clinical factsheets, as well as links to other learning programmes.

The content and activities in Module 2 are relevant to many of the GPhC registration assessment outcomes, as identified in the *GPhC Registration assessment framework*<sup>2</sup>.

The outcomes are weighted as high, medium or low according to the proportion of questions that will appear in the registration assessment:

Weighting	Proportion of questions
High	60 percent to 70 percent
Medium	25 percent to 35 percent
Low	Up to 10 percent

The table below shows which of the registration assessment outcomes you will find in Module 2, along with their weightings:

Registration assessment outcomes relevant to Module 2		Registration assessment outcome weighting
10.2.1 Implementing health policy	Access and critically evaluate evidence to support the safe, rational and cost-effective use of medicines	High
	Apply knowledge of current pharmacy-related policy to improve health outcomes	Medium
10.2.2 Validating therapeutic approaches and supplying prescribed and over-the-counter medicines	Identify and employ the appropriate diagnostic or physiological testing techniques in order to promote health	High
	Identify inappropriate health behaviours and recommend suitable approaches to interventions	Medium
	Instruct patients in the safe and effective use of their medicines and devices	High
	Analyse prescriptions for validity and clarity	Medium
	Clinically evaluate the appropriateness of prescribed medicines	High
	Provide, monitor and modify prescribed treatment to maximise health outcomes	High
10.2.4 Working with patients and the public	Identify and employ the appropriate diagnostic or physiological testing techniques to use in clinical decision making	High

Module 2 cases mapping to GPhC Registration assessment framework<sup>2</sup>

The registration assessment will include at least one question on each of the high-risk medicines or groups of medicines listed in the GPhC Registration assessment framework<sup>2</sup>. The Module 2 cases contain information and resources for some of these high-risk medicines.

Below, we have listed the therapeutic areas, topics and high-risk medicines relevant to each case and mapped this to the GPhC Registration assessment framework<sup>2</sup> so you can see how the Module 2 cases can support your registration assessment preparation.

Module 2 cases	Therapeutic areas, topics and high-risk medicines	Registration assessment outcome weighting
----------------	---	---

<p>Case 1 Gemma Lyle</p> 	Therapeutic areas	Asthma	Medium
		Pneumonia	High
		Sepsis	High
	Topics	Inhaler technique	High
		Common clinical conditions and minor ailments	High
		Red flags	High
		Clinical history-taking	High
		Smoking cessation	Medium
		Documenting in patient clinical records	Low
	High-risk medicines	Antibiotics	High

<p>Case 2 Reena Doshi</p> 	Therapeutic areas	Urinary tract infections	High
		Chronic kidney disease (CKD)	High
		Acute kidney injury (AKI)	High
		Constipation	Medium
		Osteoporosis	Low
	Topics	Antimicrobial stewardship	High
		Biochemistry	High
		Polypharmacy	High
		Medicines for older people	High
	High risk medicines	Antibiotics	High
Antihypertensives		High	
Opiates		High	

Module 2 cases	Therapeutic areas, topics and high-risk medicines	Registration assessment outcome weighting
----------------	---	---

<p><b>Case 3</b> Simon Lema</p> 	Therapeutic areas	Type 2 diabetes	High
		Coronary heart disease	High
	Topics	Transfer of care	Medium
		Medicines reconciliation	High
		Biochemistry	High
	High-risk medicines	Antidiabetic medicines	High
Antihypertensives		High	

<p><b>Case 4</b> Darren Jenkins</p> 	Therapeutic areas	Atrial fibrillation	High
		Topics	Red flags
	Clinical history-taking		High
	Mental health		High
	Lifestyle changes and social prescribing		High
	High-risk medicines	Anticoagulants	High

**References**

1. NHS. *Learning Hub*. No Date.  
[www.learninghub.nhs.uk](http://www.learninghub.nhs.uk)
2. General Pharmaceutical Council. *Registration assessment framework for sittings in 2020 and 2021*. No Date.  
[www.pharmacyregulation.org/sites/default/files/document/registration-assessment-framework-for-sittings-in-2020-and-2021.pdf](http://www.pharmacyregulation.org/sites/default/files/document/registration-assessment-framework-for-sittings-in-2020-and-2021.pdf)

**Document date:** 11 November 2020  
**Version number:** 1.0  
**Latest review:** N/A  
**Next review due:** 11 November 2021